Multi-Country Prospective ObserVAtionaL, Cohort Study of Patients With Moderate to Severe Chronic PlaqUE Psoriasis (VALUE)

CompletadoClinicalTrials.gov

ID: NCT03982394Tipo: OBSERVATIONALInicio: 1 de jul de 2019Fin estimado: 2 de sept de 2025

Traducción no disponible, mostrando original

Resumen

This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's judgement at time of recruitment.
Participant starting any approved treatment for psoriasis and physician's decision must be reached prior to recruitment in the study.
Participant willing to continue with study documentation after cessation of therapy.

Criterios de exclusión

Unwillingness or inability to comply with study requirements.
Participation in an interventional clinical trial, concurrently or within the last 30 days. Participation in a post-market observational study (PMOS) or Registry is acceptable.

Ubicaciones

Emiliano Baccarini Priv Practice /ID# 218581

Lomas de Zamora, Buenos Aires, Argentina

Hospital Universitario Austral /ID# 217540

Pilar, Buenos Aires, Argentina

Stringa Dermatologia /ID# 218450

Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina